Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
14
10
2018
revised:
29
12
2018
accepted:
11
02
2019
entrez:
5
5
2019
pubmed:
6
5
2019
medline:
8
7
2020
Statut:
ppublish
Résumé
The Surveillance, Epidemiology, and End Results (SEER) Program recently released data on brain metastases (BM) diagnosed during primary cancer staging workup ("synchronous" BM, or SBM); this study examines the incidence of SBM compared with that of lifetime BM (LBM) identified using Medicare claims for patients diagnosed with lung cancer, breast cancer, or melanoma. Incidence proportions (IP) and age-adjusted rates for each of SEER SBM and Medicare LBM are presented along with measures of concordance between the two sources of data, where Medicare LBM were defined by several combinations of diagnosis and putative diagnostic imaging procedure codes. The SBM IP in lung, breast, and melanoma cancers were 9.6%, 0.3%, and 1.1%, respectively; the corresponding LBM IP were 13.5%, 1.8%, and 3.6%. The greatest SBM IP among patients with lung cancer was 13.4% for non-small cell lung cancer, and among patients with breast cancer was 0.7% for triple-negative breast cancer. The greatest LBM IP among lung cancers was 23.1% in small-cell lung cancer, and among breast cancers was 4.2% for cases of the triple negative subtype. Using a large dataset that is representative of the elderly population in the United States, these analyses estimate synchronous and lifetime incidence of BM in lung cancers, breast cancers, and melanomas. These and other population-based estimates may be used to guide development of BM screening policy and evaluation of real-world data sources.
Sections du résumé
BACKGROUND
The Surveillance, Epidemiology, and End Results (SEER) Program recently released data on brain metastases (BM) diagnosed during primary cancer staging workup ("synchronous" BM, or SBM); this study examines the incidence of SBM compared with that of lifetime BM (LBM) identified using Medicare claims for patients diagnosed with lung cancer, breast cancer, or melanoma.
METHODS
Incidence proportions (IP) and age-adjusted rates for each of SEER SBM and Medicare LBM are presented along with measures of concordance between the two sources of data, where Medicare LBM were defined by several combinations of diagnosis and putative diagnostic imaging procedure codes.
RESULTS
The SBM IP in lung, breast, and melanoma cancers were 9.6%, 0.3%, and 1.1%, respectively; the corresponding LBM IP were 13.5%, 1.8%, and 3.6%. The greatest SBM IP among patients with lung cancer was 13.4% for non-small cell lung cancer, and among patients with breast cancer was 0.7% for triple-negative breast cancer. The greatest LBM IP among lung cancers was 23.1% in small-cell lung cancer, and among breast cancers was 4.2% for cases of the triple negative subtype.
CONCLUSIONS
Using a large dataset that is representative of the elderly population in the United States, these analyses estimate synchronous and lifetime incidence of BM in lung cancers, breast cancers, and melanomas.
IMPACT
These and other population-based estimates may be used to guide development of BM screening policy and evaluation of real-world data sources.
Identifiants
pubmed: 31053636
pii: 28/5/917
doi: 10.1158/1055-9965.EPI-18-1116
pmc: PMC6506177
mid: NIHMS1522077
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-925Subventions
Organisme : NCI NIH HHS
ID : R01 CA217956
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP003831
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.
Références
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1141-7
pubmed: 19327899
Lung Cancer. 2007 Sep;57(3):253-60
pubmed: 17451842
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
Am J Surg Pathol. 2006 Sep;30(9):1097-104
pubmed: 16931954
Lancet Oncol. 2008 Mar;9(3):222-31
pubmed: 18282806
Am J Clin Oncol. 2011 Dec;34(6):603-10
pubmed: 21150567
Hum Biol. 1966 Sep;38(3):309-17
pubmed: 5977534
Lancet Oncol. 2017 May;18(5):663-671
pubmed: 28343976
Med Care. 1999 Jul;37(7):706-11
pubmed: 10424641
Br J Cancer. 2001 Apr 6;84(7):903-9
pubmed: 11286469
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
N Engl J Med. 2006 Jan 26;354(4):333-42
pubmed: 16436765
J Neurooncol. 2017 Aug;134(1):55-64
pubmed: 28567587
Neuro Oncol. 2017 Oct 19;19(11):1511-1521
pubmed: 28444227
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:21-8
pubmed: 22552976
Med Care. 2015 Jul;53(7):e49-57
pubmed: 23524464
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
JAMA Oncol. 2017 Aug 01;3(8):1069-1077
pubmed: 28301662
Eur J Cancer. 1997 Oct;33(11):1752-8
pubmed: 9470828
Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11538-42
pubmed: 1454845
Handb Clin Neurol. 2018;149:27-42
pubmed: 29307358
Ann Oncol. 2009 Apr;20(4):621-7
pubmed: 19150943
Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v
pubmed: 21109143
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
Cancer. 1996 Oct 15;78(8):1781-8
pubmed: 8859192
Oncologist. 2011;16(1):82-6
pubmed: 21212425
J Clin Oncol. 2011 Jan 20;29(3):272-8
pubmed: 21135270
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
J Neurooncol. 2009 Dec;95(3):427-431
pubmed: 19562256
J Neurooncol. 2000 Jul;48(3):243-8
pubmed: 11100822
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688